Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA

Contributed by: GlobeNewswire

Tags

ILAP

More Like This

Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases

AOP Health CEO Martin Steinhart (Copyright: AOP Health/Studio Koekart)

Cancer Therapy: AOP Health Investigates a New Approach Targeting Cancer Stem Cells

PR Newswire associated0

Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes

PR Newswire associated0

Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab

Professor Jean-Jacques Kiladjian, University of Paris, France Photo credit: AOP Health/Lorenz Paulus

Hematology/Oncology: AOP Health’s Expanding Clinical Research Program Delivers New Results

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta

Forge Biologics’ Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is Granted UK’s Innovation Passport Designation

Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH